NDAINJECTIONINJECTABLE
Approved
Oct 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
AMINOCAPROIC ACID (aminocaproic acid) by Baxter International is clinical pharmacology the fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Approved for anemia. First approved in 1982.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Aminocaproic acid is a fibrinolysis inhibitor that works by blocking plasminogen activators and reducing antiplasmin activity. It is indicated for anemia and is administered via injection. The drug penetrates extravascular and intravascular compartments, with renal excretion as the primary elimination route.
LOE Approaching
Product approaching loss of exclusivity with minimal commercial spending signals limited growth opportunities and likely consolidated team structures.
Mechanism of Action
CLINICAL PHARMACOLOGY The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2…
Indications (1)
Worked on AMINOCAPROIC ACID at Baxter International? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.